Evidence map›Paper›PMID 34847066›Full record

ArticleAging2021

Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test.

Oleksandr Demidenko, Diogo Barardo, Valery Budovskii, Robb Finnemore, Francis R Palmer, Brian K Kennedy, Yelena V Budovskaya

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07114536 (A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate theEffects of Calcium Alpha-Ketoglutarate Supplementation on BiologicalAging, Physical Performance, and Metabolic Health in Middle-Aged andOlder Adults), which is not on this map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07114536 naactive not recruitingnot on this mapstarted 2025, after this paper: background citation

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate theEffects of Calcium Alpha-Ketoglutarate Supplementation on BiologicalAging, Physical Performance, and Metabolic Health in Middle-Aged andOlder Adults

TypeinterventionalSponsorShenzhen Hygieia Biotech Co., LtdRan2025 to 2026Enrolled30ConditionsAgingArmsCalcium-a-ketoglutarate, Placebo(starch)
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Oleksandr DemidenkoTruMe Inc., Alameda, CA 94502, USA.
Diogo BarardoHealthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University Singapore, Singapore 117456, Singapore.
Valery BudovskiiTruMe Inc., Alameda, CA 94502, USA.
Robb FinnemorePonce de Leon Health, Fernandina, FL 32034, USA.
Francis R PalmerPonce de Leon Health, Fernandina, FL 32034, USA.
Brian K KennedyHealthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University Singapore, Singapore 117456, Singapore.
Yelena V BudovskayaTruMe Inc., Alameda, CA 94502, USA.
Longevity Biotech (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The search continues for possible interventions that delay and/or reverse biological aging, resulting in extended healthspan and lifespan. Interventions delaying aging in animal models are well established; however, most lack validation in humans. The length of human lifespan makes it impractical to perform survival analysis. Instead, aging biomarkers, such as DNA methylation (DNAm) clocks, have been developed to monitor biological age. Herein we report a retrospective analysis of DNA methylation age in 42 individuals taking Rejuvant®, an alpha-ketoglutarate based formulation, for an average period of 7 months. DNAm testing was performed at baseline and by the end of treatment with Rejuvant® supplementation. Remarkably, individuals showed an average decrease in biological aging of 8 years (p-value=6.538x10

Indexed as

Dietary SupplementsKetoglutaric AcidsVitaminsAdultAgedAgingDNA MethylationFemaleGeroscienceHumansMaleMiddle AgedKetoglutaric AcidsVitaminsagingalpha-ketoglutarate (AKG)biologic ageDNA methylationRejuvant

Identifiers

PMID34847066
PMCPMC8660611
OpenAlexW3216480419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.